Ruthenium anti-cancer drugs

Last updated

Ruthenium anti-cancer drugs are coordination complexes of ruthenium complexes that have anticancer properties. They promise to provide alternatives to platinum-based drugs for anticancer therapy. [1] [2] No ruthenium anti-cancer drug has been commercialized.

Contents

Since 1979, when Cisplatin entered clinical trials, there has been continuing interest in alternative metal-based drugs. [3] The leading ruthenium-based candidates are BOLD-100 and TLD-1433. Other ruthenium based therapeutics that have been tested clinically include NAMI-A and KP1019. The first ruthenium-based drug to enter clinical trials was NAMI-A. More ruthenium drugs are still under development. Ruthenium complexes as anticancer drugs were originally designed to mimic platinum drugs for targeting DNA, [4] but emerging ruthenium compounds have shown a variety of mechanisms of actions, which include ROS generation, and as Endoplasmic reticulum stress agents. [5]

Properties of ruthenium complexes

Ruthenium has numerous properties that qualify it as an antineoplastic drug contender. [4] [6]

Oxidation states and geometry

Ruthenium complexes typically adopt oxidation states II and III [7] The geometry assumed by most ruthenium complexes is octahedral, which differs from the square planar molecular geometry typical for platinum(II). The presence of six ligands allows for tuning of the complexes' electronic and steric properties. [1] [8] [9] Its partially filled 4d sub-shell allows it to form complexes that are useful for a wide variety of applications including catalysis, electronics, photochemistry, biosensors and anticancer drugs. [10] [11]

Ligand exchange rates

The rate of ligand exchange for ruthenium complexes is relatively slow in comparison with other transition metal complexes. The range of these exchange rates is around 10−2 to 10−4 s−1 which is on the scale of an average cell’s lifetime, giving the drug high kinetic stability and minimizing side reactions. [1] This allows the Ru complex to remain intact as it approaches the target as well as remain viable throughout its interaction with the cells. It is also possible through ligand variation to precisely tune the exchange kinetics, allowing a large degree of control over the complex’s stability. [12]

Activation

The theory of "activation by reduction" is based on the understanding that Ru(II) complexes are generally more reactive than Ru(III) complexes. As cancer cells are generally growing and multiplying much more rapidly than normal healthy cells, this creates an environment that is less oxygen-rich due to the raised metabolic rate. When this is paired with the tendency of cancerous cells to contain higher levels of glutathione and a lower pH, a chemically reducing environment is created. [1] This theoretically allows for ruthenium complexes to be administered as much less active, non-toxic Ru(III) compounds (as a prodrug), which can be activated solely at the site of the cancerous cells. [1] The reduction is thought to occur by mitochondrial proteins or microsomal single electron transfer proteins, though it may also occur by trans-membrane electron transport systems which reside outside the cell – implying that entry to the cancerous cells may not be required for the drug to be effective. [7] In theory it is also possible for the ruthenium compounds to be oxidized back to their inactive form if it leaves the cancerous environment. This phenomenon remains a theory, and has been primarily demonstrated in vitro . [4]

Although this theory is attractive, convenient, and grounded in fundamental ruthenium chemistry, this theory falls apart when investigated under in vivo . A direct contradiction of this theory was proven using XANES and BOLD-100. This study examined several tissues (tumor included) of SW480-bearing mice for 24 hours after administration of BOLD-100. This study showed that the Ru(III) oxidation state persists, and since BOLD-100 has significant biological effects within that 24-hour time point, this directly contradicts the "activation by reduction" mechanism. [13]

Biological transportation

3D rendering of human serum albumin (HSA) PDB 1AO6-HSA.png
3D rendering of human serum albumin (HSA)

The ruthenium complex BOLD-100 binds to serum albumin as established by X-ray crystallography. This adduct is proposed to facilitate uptake. [14] The levels of serum albumin in these cancerous cells are greatly increased, which may contribute to the lower toxicity associated to the ruthenium drugs in comparison to platinum. [12]

Prospective ruthenium anti-cancer drugs

BOLD-100

BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is the most clinically advanced ruthenium-based therapeutic. As of November 2021, BOLD-100 was being tested in a Phase 1b clinical trial in patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX. [15]

NAMI

Chemical structure of sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)] (BOLD-100) BOLD-100-Na.tif
Chemical structure of sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)] (BOLD-100)

NAMI {Na[trans-RuCl4](DMSO)(imida)]} and NAMI-A {H2Im[trans-RuCl4(DMSO)HIm[imidH] are salts that were investigated as anti-cancer drugs. [6] NAMI-A is considered a pro-drug and is inactive at physiological pH of 7.4. [1] Cancer cells generally contain a lower oxygen concentration as well as higher levels of glutathione and a lower pH than normal tissues creating a reducing environment. Upon entering cancer cells NAMI-A is activated by the reduction of Ru(III) to Ru(II) to form the active anti-cancer agent.[ citation needed ]

KP1019

KP1019, a salt of trans-tetrachlorobis(indazole)ruthenate(III) were investigated as drugs. [16] KP1019 has an octahedral structure with two trans N-donor indazole and four chloride ligands in the equatorial plane. [17] [18] [19] It has a low solubility in water, which makes it difficult to transport in the bloodstream. Instead KP1339[ clarification needed ] is used as a preparation of KP1019 in clinical trials, since it has a better solubility as a sodium salt. [19]

Proteins and other N-donors are good binding partners for KP1019. [20] [21] [22]

Especially transferrin and albumin are good binding partners. [23] The overall method of action for KP1019 needs to be supported further.

Tumor cells have a high requirement of iron, which results in a large concentration of transferrin. Ru(III) complexes bind to transferrin and are proposed to interfere with iron uptake. [24] [25]

RAPTA

RAPTA compounds are ruthenium–arene complexes bearing the 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane ligand. [26] The complex has a piano stool geometry. The PTA ligand confers water solubility, and the two chloride ligands are labile. [8] RAPTA compounds have low general toxicity that apparently reduces the side-effects associated with chemotherapy. [8]

RAED

Ruthenium diamine complexes have been investigated as potential anticancer drugs. [27] [28] RAED compounds are ruthenium–arene complexes bearing the 1,2-ethylenediamine ligand.

The ruthenium diamine complexes form adducts with guanine. [29] Methylation or substitution on en-NH, which prevent the hydrogen bonding, can lead to the loss of cytotoxic activity of the complex toward cancer cell. [30] [31] The ethylenediamine ligand suppresses reactions of the complex with amino acid residues. The Ru(II) complexes have a higher affinity to DNA in the presence of protein than the Ru(III) compounds, such as NAMI-A. [32]

Related Research Articles

<span class="mw-page-title-main">Cisplatin</span> Pharmaceutical drug

Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein.

<span class="mw-page-title-main">Metal ammine complex</span>

In coordination chemistry, metal ammine complexes are metal complexes containing at least one ammonia ligand. "Ammine" is spelled this way due to historical reasons; in contrast, alkyl or aryl bearing ligands are spelt with a single "m". Almost all metal ions bind ammonia as a ligand, but the most prevalent examples of ammine complexes are for Cr(III), Co(III), Ni(II), Cu(II) as well as several platinum group metals.

<span class="mw-page-title-main">Sandwich compound</span> Chemical compound made of two ring ligands bound to a metal

In organometallic chemistry, a sandwich compound is a chemical compound featuring a metal bound by haptic, covalent bonds to two arene (ring) ligands. The arenes have the formula CnHn, substituted derivatives and heterocyclic derivatives. Because the metal is usually situated between the two rings, it is said to be "sandwiched". A special class of sandwich complexes are the metallocenes.

<span class="mw-page-title-main">Dichlorotetrakis(dimethylsulfoxide)ruthenium(II)</span> Chemical compound

Dichlorotetrakis(dimethyl sulfoxide) ruthenium(II) describes coordination compounds with the formula RuCl2(dmso)4, where DMSO is dimethylsulfoxide. Both cis and trans isomers are known, but the cis isomer is more common. The cis isomer is a yellow, air-stable solid that is soluble in some organic solvents. These compounds have attracted attention as possible anti-cancer drugs.

<span class="mw-page-title-main">Organoruthenium chemistry</span>

Organoruthenium chemistry is the chemistry of organometallic compounds containing a carbon to ruthenium chemical bond. Several organoruthenium catalysts are of commercial interest and organoruthenium compounds have been considered for cancer therapy. The chemistry has some stoichiometric similarities with organoiron chemistry, as iron is directly above ruthenium in group 8 of the periodic table. The most important reagents for the introduction of ruthenium are ruthenium(III) chloride and triruthenium dodecacarbonyl.

<span class="mw-page-title-main">Stephen J. Lippard</span> American chemist

Stephen James Lippard is the Arthur Amos Noyes Emeritus Professor of Chemistry at the Massachusetts Institute of Technology. He is considered one of the founders of bioinorganic chemistry, studying the interactions of nonliving substances such as metals with biological systems. He is also considered a founder of metalloneurochemistry, the study of metal ions and their effects in the brain and nervous system. He has done pioneering work in understanding protein structure and synthesis, the enzymatic functions of methane monooxygenase (MMO), and the mechanisms of cisplatin anticancer drugs. His work has applications for the treatment of cancer, for bioremediation of the environment, and for the development of synthetic methanol-based fuels.

<span class="mw-page-title-main">Dichlorotris(triphenylphosphine)ruthenium(II)</span> Chemical compound

Dichlorotris(triphenylphosphine)ruthenium(II) is a coordination complex of ruthenium. It is a chocolate brown solid that is soluble in organic solvents such as benzene. The compound is used as a precursor to other complexes including those used in homogeneous catalysis.

<span class="mw-page-title-main">NAMI-A</span> Chemical compound

NAMI-A is the imidazolium]] salt of the coordination complex [RuCl4(dmso)(C3N2H4)]− where dmso is dimethylsulfoxide and C3N2H4 is imidazole Together with KP1019 and BOLD-100, NAMI-A has been investigated as an anticancer agent.

A metal carbido complex is a coordination complex that contains a carbon atom as a ligand. They are analogous to metal nitrido complexes. Carbido complexes are a molecular subclass of carbides, which are prevalent in organometallic and inorganic chemistry. Carbido complexes represent models for intermediates in Fischer–Tropsch synthesis, olefin metathesis, and related catalytic industrial processes. Ruthenium-based carbido complexes are by far the most synthesized and characterized to date. Although, complexes containing chromium, gold, iron, nickel, molybdenum, osmium, rhenium, and tungsten cores are also known. Mixed-metal carbides are also known.

<span class="mw-page-title-main">Half sandwich compound</span> Class of coordination compounds

Half sandwich compounds, also known as piano stool complexes, are organometallic complexes that feature a cyclic polyhapto ligand bound to an MLn center, where L is a unidentate ligand. Thousands of such complexes are known. Well-known examples include cyclobutadieneiron tricarbonyl and (C5H5)TiCl3. Commercially useful examples include (C5H5)Co(CO)2, which is used in the synthesis of substituted pyridines, and methylcyclopentadienyl manganese tricarbonyl, an antiknock agent in petrol.

<span class="mw-page-title-main">Bernhard Keppler</span> German chemistry professor

Bernhard K. Keppler is a German bioinorganic chemist and physician. He is chair of inorganic chemistry at the University of Vienna, head of the Institute of Inorganic Chemistry and dean of the Faculty of Chemistry.

DNA-binding metallo-intercalators are positively charged, planar, polycyclic, aromatic compounds that unwind the DNA double helix and insert themselves between DNA base pairs. Metallo-intercalators insert themselves between two intact base pairs without expelling or replacing the original nitrogenous bases; the hydrogen bonds between the nitrogenous bases at the site of intercalation remain unbroken. In addition to π-stacking between the aromatic regions of the intercalator and the nitrogenous bases of DNA, intercalation is stabilized by van der Waals, hydrophobic, electrostatic, and entropic interactions. This ability to bind to specific DNA base pairs allows for potential therapeutic applications of metallo-intercalators.

<span class="mw-page-title-main">Christian Hartinger</span> New Zealand bioinorganic chemist known for his work in metal-based anticancer drugs

Christian G. Hartinger is an Austrian-born New Zealand bioinorganic chemist known for his work in metal-based anticancer drugs. In 2022 he was elected a Fellow of the Royal Society Te Apārangi.

<span class="mw-page-title-main">KP1019</span> Chemical compound

KP1019, or indazole trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is one of four ruthenium anti-cancer drugs to enter into phase I clinical trials, the others being BOLD-100, NAMI-A and TLD-1433. Research into ruthenium-based drugs has provided novel alternatives for platinum-based chemotherapeutics such as Cisplatin and its derivatives. KP1019 is useful for metastatic tumors and cis-platin resistant tumors. It exhibits potent cytotoxicity against primary tumors, particularly in colorectal cancer.

Che Chi-ming, is a Hong Kong chemist currently holding Zhou Guangzhao Professorship in Natural Sciences, following a Dr. Hui Wai-Haan's Chair of Chemistry at the University of Hong Kong (HKU). In 1995, he became the first scientist from Hong Kong to be elected as a member of the Chinese Academy of Sciences. He is known for extensive work in inorganic chemistry, photochemistry, and medicinal chemistry.

<span class="mw-page-title-main">Transplatin</span> Chemical compound

trans-Dichlorodiammineplatinum(II) is the trans isomer of the coordination complex with the formula trans-PtCl2(NH3)2, sometimes called transplatin. It is a yellow solid with low solubility in water but good solubility in DMF. The existence of two isomers of PtCl2(NH3)2 led Alfred Werner to propose square planar molecular geometry. It belongs to the molecular symmetry point group D2h.

Metal arene complexes are organometallic compounds of the formula (C6R6)xMLy. Common classes are of the type (C6R6)ML3 and (C6R6)2M. These compounds are reagents in inorganic and organic synthesis. The principles that describe arene complexes extend to related organic ligands such as many heterocycles (e.g. thiophene) and polycyclic aromatic compounds (e.g. naphthalene).

RAPTA is a class of experimental cancer drugs. They consist of a central ruthenium(II) atom complexed to an arene group, chlorides, and 1,3,5-triaza-7-phosphaadamantane (PTA) forming an organoruthenium half-sandwich compound. Other related ruthenium anti-cancer drugs include NAMI-A, KP1019 and BOLD-100.

<span class="mw-page-title-main">Transition metal thioether complex</span>

Transition metal thioether complexes comprise coordination complexes of thioether (R2S) ligands. The inventory is extensive.

<span class="mw-page-title-main">BOLD-100</span> Experimental cancer drug

BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is a ruthenium-based anti-cancer therapeutic in clinical development. As of November 2021, BOLD-100 was being tested in a Phase 1b clinical trial in patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 is being developed by Bold Therapeutics Inc.

References

  1. 1 2 3 4 5 6 Antonarakis, Emmanuel S.; Emadi, Ashkan (2010). "Ruthenium-based chemotherapeutics: Are they ready for prime time?". Cancer Chemotherapy and Pharmacology. 66 (1): 1–9. doi:10.1007/s00280-010-1293-1. PMC   4020437 . PMID   20213076.
  2. ↑ Bergamo, A.; Gaiddon, C.; Schellens, J.H.M.; Beijnen, J.H.; Sava, G. (2012). "Approaching tumour therapy beyond platinum drugs". Journal of Inorganic Biochemistry. 106 (1): 90–9. doi:10.1016/j.jinorgbio.2011.09.030. PMID   22112845.
  3. ↑ Clarke, M.J.; Bitler, S.; Rennert, D.; Buchbinder, M.; Kelman, A.D. (1980). "Reduction and Subsequent Binding of Ruthenium Ions Catalyzed by Subcellular Components". Journal of Inorganic Biochemistry. 12 (1): 79–87. doi:10.1016/S0162-0134(00)80045-8. PMID   7373292.
  4. 1 2 3 Bergamo, Alberta; Sava, Gianni (2011). "Ruthenium anticancer compounds: Myths and realities of the emerging metal-based drugs". Dalton Transactions. 40 (31): 7817–23. doi:10.1039/C0DT01816C. PMID   21629963.
  5. ↑ Mjos, Katja Dralle; Orvig, Chris (2014-04-23). "Metallodrugs in Medicinal Inorganic Chemistry". Chemical Reviews. 114 (8): 4540–4563. doi: 10.1021/cr400460s . ISSN   0009-2665. PMID   24456146.
  6. 1 2 Amin, Amr; Buratovich, Michael (2009). "New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field". Mini-Reviews in Medicinal Chemistry. 9 (13): 1489–503. doi:10.2174/138955709790361566. PMID   20205631.
  7. 1 2 Page, Simon (1 January 2012). "Ruthenium compounds as anticancer agents". Education in Chemistry . Vol. 49, no. 1. Royal Society of Chemistry. pp. 26–29.
  8. 1 2 3 Ang, Wee Han; Casini, Angela; Sava, Gianni; Dyson, Paul J. (2011). "Organometallic ruthenium-based antitumor compounds with novel modes of action". Journal of Organometallic Chemistry. 696 (5): 989–98. doi:10.1016/j.jorganchem.2010.11.009.
  9. ↑ Gopal YN, Jayaraju D, Kondapi AK (April 1999). "Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action". Biochemistry. 38 (14): 4382–8. doi:10.1021/bi981990s. PMID   10194357.
  10. ↑ Kostova I (2006). "Ruthenium complexes as anticancer agents". Current Medicinal Chemistry. 13 (9): 1085–107. doi:10.2174/092986706776360941. PMID   16611086.
  11. ↑ Antonarakis ES, Emadi A (May 2010). "Ruthenium-based chemotherapeutics: are they ready for prime time?". Cancer Chemotherapy and Pharmacology. 66 (1): 1–9. doi:10.1007/s00280-010-1293-1. PMC   4020437 . PMID   20213076.
  12. 1 2 Bruijnincx, Pieter C.A.; Sadler, Peter J. (2009). Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. Advances in Inorganic Chemistry. Vol. 61. pp. 1–62. doi:10.1016/S0898-8838(09)00201-3. ISBN   9780123750334. PMC   3024542 . PMID   21258628.
  13. ↑ Blazevic, Amir; Hummer, Alfred A.; Heffeter, Petra; Berger, Walter; Filipits, Martin; Cibin, Giannantonio; Keppler, Bernhard K.; Rompel, Annette (23 January 2017). "Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse". Scientific Reports. 7 (1): 40966. Bibcode:2017NatSR...740966B. doi:10.1038/srep40966. PMC   5256101 . PMID   28112202.
  14. ↑ Bijelic, Aleksandar; Theiner, Sarah; Keppler, Bernhard K.; Rompel, Annette (23 June 2016). "X-ray Structure Analysis of Indazolium trans- [Tetrachlorobis(1 H -indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism". Journal of Medicinal Chemistry. 59 (12): 5894–5903. doi:10.1021/acs.jmedchem.6b00600. PMC   4921950 . PMID   27196130.
  15. ↑ Clinical trial number NCT04421820 NCT04421820 for "BOLD-100 in combination with FOLFOX for the treatment of advanced solid tumours." at ClinicalTrials.gov
  16. ↑ Galanski, M.; Arion, V.; Jakupec, M.; Keppler, B. (2003). "Recent Developments in the Field of Tumor-Inhibiting Metal Complexes". Current Pharmaceutical Design. 9 (25): 2078–89. doi:10.2174/1381612033454180. PMID   14529417. S2CID   9170949.
  17. ↑ Peti, Wolfgang; Pieper, Thomas; Sommer, Martina; Keppler, Bernhard K.; Giester, Gerald (1999). "Synthesis of Tumor-Inhibiting Complex Salts Containing the Anion trans-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenylphosphonium Salt". European Journal of Inorganic Chemistry. 1999 (9): 1551–5. doi:10.1002/(SICI)1099-0682(199909)1999:9<1551::AID-EJIC1551>3.0.CO;2-7.
  18. ↑ Jakupec, M. A.; Galanski, M.; Keppler, B. K. (2003). "Tumour-inhibiting platinum complexes—state of the art and future perspectives". Reviews of Physiology, Biochemistry and Pharmacology. Vol. 146. pp. 1–53. doi:10.1007/s10254-002-0001-x. ISBN   978-3-540-00228-4. PMID   12605304.
  19. 1 2 Hartinger, Christian G.; Zorbas-Seifried, Stefanie; Jakupec, Michael A.; Kynast, Bernd; Zorbas, Haralabos; Keppler, Bernhard K. (2006). "From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)". Journal of Inorganic Biochemistry. 100 (5–6): 891–904. doi:10.1016/j.jinorgbio.2006.02.013. PMID   16603249.
  20. ↑ Egger, Alexander; Arion, Vladimir B.; Reisner, Erwin; Cebrián-Losantos, Berta; Shova, Sergiu; Trettenhahn, Günter; Keppler, Bernhard K. (2005). "Reactions of Potent Antitumor Complex trans-[RuIIICl4(indazole)2]− with a DNA-Relevant Nucleobase and Thioethers: Insight into Biological Action". Inorganic Chemistry. 44 (1): 122–32. doi:10.1021/ic048967h. PMID   15627368.
  21. ↑ Smith, Clyde A.; Sutherland-Smith, Andrew J.; Kratz, Felix; Baker, E. N.; Keppler, B. H. (1996). "Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses". Journal of Biological Inorganic Chemistry. 1 (5): 424–31. doi:10.1007/s007750050074. S2CID   10270542.
  22. ↑ Trynda-Lemiesz, Lilianna; Karaczyn, Aldona; Keppler, Bernhard K; Kozlowski, Henryk (2000). "Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III)". Journal of Inorganic Biochemistry. 78 (4): 341–6. doi:10.1016/S0162-0134(00)00062-3. PMID   10857915.
  23. ↑ Sulyok, M.; Hann, S.; Hartinger, C. G.; Keppler, B. K.; Stingeder, G.; Koellensperger, G. (2005). "Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins". Journal of Analytical Atomic Spectrometry. 20 (9): 856–63. doi:10.1039/B508060F.
  24. ↑ Kratz, F; Hartmann, M; Keppler, B; Messori, L (1994). "The binding properties of two antitumor ruthenium(III) complexes to apotransferrin". The Journal of Biological Chemistry. 269 (4): 2581–8. doi: 10.1016/S0021-9258(17)41984-3 . PMID   8300587.
  25. ↑ Pongratz, Martina; Schluga, Petra; Jakupec, Michael A.; Arion, Vladimir B.; Hartinger, Christian G.; Allmaier, Günter; Keppler, Bernhard K. (2004). "Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy". Journal of Analytical Atomic Spectrometry. 19: 46–51. doi:10.1039/B309160K.
  26. ↑ Tan, Yu Qian; Dyson, Paul J.; Ang, Wee Han (2011). "Acetal-Functionalized RAPTA Complexes for Conjugation and Labeling". Organometallics. 30 (21): 5965–71. doi:10.1021/om200783r.
  27. ↑ Morris, Robert E.; Aird, Rhona E.; del Socorro Murdoch, Piedad; Chen, Haimei; Cummings, Jeff; Hughes, Nathan D.; Parsons, Simon; Parkin, Andrew; Boyd, Gary; Jodrell, Duncan I.; Sadler, Peter J. (2001). "Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes". Journal of Medicinal Chemistry. 44 (22): 3616–3621. doi:10.1021/jm010051m. ISSN   0022-2623. PMID   11606126.
  28. ↑ Chen H, Parkinson JA, Parsons S, Coxall RA, Gould RO, Sadler PJ (2002). "Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts". Journal of the American Chemical Society. 124 (12): 3064–82. doi:10.1021/ja017482e. PMID   11902898.
  29. ↑ Chen H, Parkinson JA, Morris RE, Sadler PJ (2003). "Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms". Journal of the American Chemical Society. 125 (1): 173–86. doi:10.1021/ja027719m. PMID   12515520.
  30. ↑ Bugarcic T, Habtemariam A, Deeth RJ, Fabbiani FP, Parsons S, Sadler PJ (2009). "Ruthenium(II) arene anticancer complexes with redox-active diamine ligands". Inorganic Chemistry. 48 (19): 9444–53. doi:10.1021/ic9013366. PMID   19780621.
  31. ↑ Habtemariam A, Melchart M, Fernandez R, Parsons S, Oswald ID, Parkin A, Fabbiani FP, Davidson JE, Dawson A, Aird RE, Jodrell DI, Sadler PJ (2006). "Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands". Journal of Medicinal Chemistry. 49 (23): 6858–68. doi:10.1021/jm060596m. PMID   17154516.
  32. ↑ Wang F, Chen H, Parkinson JA, Murdoch Pdel S, Sadler PJ (2002). "Reactions of a ruthenium(II) arene antitumor complex with cysteine and methionine". Inorganic Chemistry. 41 (17): 4509–23. doi:10.1021/ic025538f. PMID   12184769.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.